文献速递神经肿瘤神经重症

成人颅脑肿瘤切除术后立即使用非甾体抗炎药的安全性

Safety of the immediate use of nonsteroidal anti-inflammatory drugs after adult craniotomy for tumor.
PubMed 文献 · J Neurosurg · 2024-02-02

该回顾性队列研究纳入2019至2021年在本机构接受颅脑肿瘤切除术的18岁以上、估算肾小球滤过率≥60 ml/min/体表面积的患者1182例,其中114例(9.6%)在术后48小时内至少使用一剂非甾体抗炎药(NSAID)。NSAID组需重返手术室的出血风险与未使用组无显著差异(RR 3.12,95%CI 0.33-29.77,p=0.30),但NSAID组口服吗啡当量用量显著更高(中位数68 vs 30,p<0.001)。作者认为术后使用NSAID未增加需重返手术室的出血风险,但需进一步研究其作为阿片类药物节约策略的安全性。

要点

  • 颅脑肿瘤切除术后48小时内使用NSAID与需重返手术室的出血风险无显著关联(RR 3.12,95%CI 0.33-29.77,p=0.30)。
  • NSAID组与未使用组在非手术性颅内出血、术后急性肾损伤或临床显著颅外出血方面无显著差异。
  • NSAID组术后48小时内口服吗啡当量用量显著高于未使用组(中位数68 vs 30,p<0.001)。

核心结论

  • 颅脑肿瘤切除术后使用NSAID与需重返手术室的出血风险增加无关。
  • 作者注意到使用NSAID的患者阿片类药物用量更高,这可能反映了决定在术后早期使用NSAID的潜在原因。
  • 这些数据提示需进一步研究NSAID作为肾功能正常的颅内肿瘤切除患者安全、节约阿片类药物的术后疼痛管理策略。

研究设计与样本

  • 回顾性队列研究,纳入2019至2021年在本机构接受颅脑肿瘤切除术的18岁以上、估算肾小球滤过率≥60 ml/min/体表面积的患者。
  • 共审查1765份患者记录,其中1182例符合纳入分析标准。
  • 记录术后最初48小时内NSAID的使用情况。

主要发现

  • 1182例纳入分析的患者中,114例(9.6%)在颅脑术后48小时内至少使用一剂NSAID。
  • 4例(0.3%)患者发生需重返手术室的出血,其中1例来自NSAID治疗组(RR 3.12,95%CI 0.33-29.77,p=0.30)。
  • NSAID组与未使用NSAID组在非手术性颅内出血(RR 1.34,95%CI 0.54-3.35,p=0.53)、术后急性肾损伤或临床显著颅外出血方面无显著差异。
  • NSAID组口服吗啡当量用量显著高于未使用NSAID组(中位数68 vs 30,p<0.001)。

临床怎么用

  • 作者认为术后使用NSAID与需重返手术室的出血风险增加无关。
  • 作者指出使用NSAID的患者阿片类药物用量更高,可能反映选择NSAID的潜在原因。
  • 作者建议需进一步研究NSAID作为肾功能正常患者颅内肿瘤切除术后安全、节约阿片类药物的疼痛管理策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Poor pain control has a negative impact on postoperative recovery and patient satisfaction. However, overzealous pain management, particularly with opioids, can confound serial neurological assessments, increase morbidity, and predispose patients to long-term dependence. Nonsteroidal anti-inflammatory drugs (NSAIDs) are effective in treating postoperative pain and can limit opioid intake, but their use has been limited in patients undergoing craniotomy for brain tumor resection due to concerns of an increased hemorrhage risk. Herein, the authors aim to 1) address the safety of NSAID use in the immediate postoperative setting and 2) determine whether NSAID administration decreases opioid use following craniotomy for tumor resection in adult patients. METHODS: The authors conducted a retrospective cohort study of patients 18 years and older with an estimated glomerular filtration rate ≥ 60 ml/min/body surface area who had undergone craniotomy for tumor resection at their institution between 2019 and 2021. NSAID use in the first 48 hours following surgery was recorded. Primary outcomes were postoperative hemorrhage requiring a return to the operating room before hospital discharge and within 30 days of surgery. Secondary outcomes were more-than-minimal hemorrhage that did not require reoperation, acute kidney injury, and total opioid use within 48 hours after craniotomy. RESULTS: Among 1765 reviewed patient records, 1182 were eligible for inclusion in this analysis. Amid these records were 114 patients (9.6%) who had received at least one dose of an NSAID within 48 hours of their craniotomy. Four (0.3%) patients experienced bleeding requiring a return to operating room, one of whom was from the NSAID-treated group (RR 3.12, 95% CI 0.33-29.77, p = 0.30). No significant difference in nonoperative intracranial hemorrhage (RR 1.34, 95% CI 0.54-3.35, p = 0.53), postoperative acute kidney injury, or clinically significant extracranial bleeding was found between the NSAID and no-NSAID groups. Patients in the NSAID group had significantly higher oral morphine equivalent use (median 68 vs 30, p < 0.001). CONCLUSIONS: Postoperative NSAID use following craniotomy for tumor resection was not associated with an increased risk of hemorrhage requiring a return to the operating room. The authors noted higher opioid use in the patients treated with NSAIDs, which may reflect underlying reasons for the decision to treat patients with NSAIDs in the immediate postoperative period. These data warrant further investigation of NSAIDs as a safe, opioid-sparing postoperative pain management strategy in patients with normal kidney function who are undergoing intracranial tumor resection.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Perez JL, Naylor RM, Bauman MMJ, et al. Safety of the immediate use of nonsteroidal anti-inflammatory drugs after adult craniotomy for tumor. J Neurosurg. 2024. PMID: 38306640. doi:10.3171/2023.11.JNS231600

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。